SONN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SONN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Sonnet BioTherapeutics Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Sonnet BioTherapeutics Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Sonnet BioTherapeutics Holdings (NAS:SONN) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
John Markey | 10 percent owner | 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087 |
Susan Dexter | officer: Chief Technical Officer | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Albert D. Dyrness | director | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Nailesh Bhatt | director | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Pankaj Mohan | director, officer: Chairman, President and CEO | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Lori Mcneill | director | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540 |
Richard T Kenney | officer: Chief Medical Officer | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102 |
Donald J. Griffith | director | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Terence Anthony Rugg | officer: Chief Medical Officer | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
John K. Cini | officer: Chief Scientific Officer | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Raghu Rao | director | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Cross John Harry Iii | officer: Chief Financial Officer | C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540 |
Oz Rey Llc | 10 percent owner | 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701 |
Mv Amanth Llc | 10 percent owner | 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516 |
Robert Sumner Hersch | 10 percent owner | 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701 |
From GuruFocus
By ACCESSWIRE • 07-31-2023
By ACCESSWIRE ACCESSWIRE • 12-16-2022
By ACCESSWIRE ACCESSWIRE • 11-02-2022
By ACCESSWIRE ACCESSWIRE • 04-17-2023
By ACCESSWIRE • 08-14-2023
By ACCESSWIRE ACCESSWIRE • 11-02-2022
By ACCESSWIRE • 06-23-2023
By ACCESSWIRE ACCESSWIRE • 02-13-2023
By ACCESSWIRE ACCESSWIRE • 02-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.